Aster DM Healthcare Limited — Q1 FY26 earnings call

Call held 31 Jul 2025

Management summary

Aster DM Healthcare delivered a strong start to FY26, characterized by significant margin expansion and record-high ARPOB. The quarter marked a recovery in the Kerala cluster and successful rationalization of low-margin scheme businesses in Maharashtra. Management is heavily focused on the upcoming merger with Quality Care India Limited (QCIL), which will create a combined entity with over 10,350 beds and significant procurement synergies.

Highlights

  • Revenue grew 8% YoY to ₹1,078 crores, driven by a strategic shift toward high-value businesses.

  • Operating EBITDA expanded 21% YoY to ₹215 crores, with margins improving to 20.0% from 17.7%.

  • Normalized PAT rose 22% YoY to ₹90 crores, excluding one-time merger-related costs.

  • ARPOB crossed the ₹50,000 mark for the first time, registering a strong 14% YoY growth.

  • Average Length of Stay (ALOS) improved by 4%, reducing from 3.2 to 3.1 days.

  • The company announced a massive expansion plan to add 2,600 beds for Aster and 1,200 for QCIL, targeting 14,000+ beds in 2-3 years.

  • Aster Labs delivered a turnaround with EBITDA margins improving to 7.6% from 3.4% YoY.

Key financials

  1. Revenue ₹1,078 Cr +8%YoY
  2. Operating EBITDA ₹215 Cr +21%YoY
  3. EBITDA Margin 20%
  4. Normalized PAT ₹90 Cr +22%YoY
  5. ARPOB ₹50,000 +14%YoY
  6. Bed Capacity 5,197 beds +6%YoY

What they filed

Q1 FY27: revenue up 21.6%, net profit down 69.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,086 1,050 1,000 1,078 1,197 +10%1,186 +13%1,182 +18%1,311 +22%
EBITDA217 186 182 202 236 +9%202 +9%224 +23%256 +27%
Net profit106 64 86 94 121 +14%59 −8%154 +79%29 −69%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Karnataka & Maharashtra Cluster
    ₹372 Cr Revenue23.2% Operating EBITDA Margin13% Growth
  • Kerala Cluster
    5% Revenue Growth6% Sequential Volume Growth25% EBITDA Margin
  • Andhra & Telangana Cluster
    ₹118 Cr Revenue₹9 Cr Operating EBITDA7.9% EBITDA Margin
  • Aster Labs
    7.6% EBITDA Margin13.7% ROCE

Guidance & targets

Capacity

  • Aster Bed Additions Capacity · next 3-4 years · High confidence 2,600
    In the coming years, we plan to add another 2,600 beds, both Greenfield and Brownfield projects taking our capacity beyond 7,800 beds.

    — Alisha Moopen, Deputy Managing Director

  • QCIL Bed Additions Capacity · next 6-8 quarters · High confidence 1,200
    So, from a pipeline standpoint, we're looking at about 1,200 beds... We will come in for the next 6-8 quarters.

    — Varun Khanna, Group MD & CEO, QCIL

Capex

  • Aster Project Capex Capex · next 3-4 years · High confidence ₹2,000 crores
    And balance INR 2,000 crores approximately will be spent over next 3-4 years.

    — Sunil Kumar, CFO

Revenue

  • Long-term ARPOB Growth Revenue · next 3-4 years · Medium confidence 7-8%
    But on a neutral apple to apple comparison, we are looking at around a 7-8% over a period of 3-4 years.

    — Sunil Kumar, CFO

Volume

  • Long-term Volume Growth Volume · next 3-4 years · Medium confidence 7-8%
    In mid-teen growth, approximately volume should give a driving force of approximately 7-8% and balance 7-8% should come from ARPOB.

    — Sunil Kumar, CFO

Risks & concerns

  • Clinical Talent Attrition

    medium

    Attrition in clinical talent in Andhra and Telangana clusters led to higher initial costs for new hires, impacting EBITDA margins this quarter.

    Management acknowledged

  • Occupancy Dilution from New Beds

    medium

    Adding 2,600+ beds will naturally dilute occupancy percentages in the short term; management urges investors to focus on volume growth instead.

    Both acknowledged

  • Geopolitical Situation in Bangladesh

    low

    Management stated that assets in Bangladesh were not impacted and the Dhaka facility continues to improve every quarter.

    Analyst downplayed

Areas of evasion (1)

  • Specific debt quantum on QCIL books (Varun Khanna gave a general 'lower than EBITDA' answer).

Q&A highlights

3 direct
Rationalization of Scheme Business Direct
In Maharashtra, we discontinued the schemes... the scheme business was occupying more than 20% of our beds. So, we had to cut down that to make space for the other patients.

Explains why volumes were negative (-5%) in Karnataka/Maharashtra but ARPOB jumped significantly, signaling a shift to higher-margin payors.

Asked by Amey Chalke

QCIL Procurement Synergies Direct
This is the first time the 3 entities that we currently have, which is Care, KIMS and Evercare, has come together. And the procurement has got centralized across the board... Half of our, maybe more than half of our savings are coming in just from the efficiency on procurement optimization.

Quantifies the immediate ₹20 crore EBITDA uplift from pre-merger integration, proving the 'synergy wheel' is already operational.

Asked by Nikhil Mathur

Kerala Cluster Recovery and MVT Direct
MVT revenues in Kerala has jumped 12% sequentially... we have focused back again on Oman business as well as Maldives cases. It is really doing well now.

Confirms that leadership changes in Kerala have stabilized the cluster and that high-margin international patient traffic is returning.

Asked by Tausif Shaikh

1 min read 5 chapters

Detailed narrative

Strategic Pivot to High-Acuity Care Drives ARPOB

Aster achieved a milestone ARPOB of over ₹50,000, a 14% YoY increase. This was driven by a deliberate shift toward high-value specialties like Oncology, which now accounts for 11% of revenue compared to 9% in Q1 FY24. Additionally, the company improved operational efficiency by reducing ALOS from 3.2 to 3.1 days, effectively increasing capacity without adding physical beds.

Aggressive Bengaluru Expansion Strategy

Management is doubling down on the Bengaluru market, adding 1,439 beds including a new 500-bed facility in Yeswanthpur. Once complete, total capacity in the city will exceed 2,580 beds. This strategy aims to capture localized demand in a city where traffic makes travel difficult, positioning Aster as a top 3 healthcare provider in the region.

QCIL Merger Synergies Materializing Early

The proposed merger with Quality Care India Limited (QCIL) is already yielding results through pre-merger synergies. QCIL reported a ₹20 crore EBITDA uplift this quarter solely from centralized procurement and formulary compliance across its Care, KIMS, and Evercare entities. The combined entity will boast 10,350 beds across 38 hospitals, with proforma revenues of ₹2,157 crores.

Kerala Cluster Stabilizes After Leadership Changes

After several challenging quarters, the Kerala cluster saw a 5% YoY revenue growth and an 11% sequential improvement. Management attributed this to stabilized leadership and a 12% sequential jump in Medical Value Travel (MVT) revenues. The cluster maintained a healthy EBITDA margin of approximately 25% during the quarter.

Aster Labs and Pharmacy Turnaround

Aster Labs saw its EBITDA margins more than double to 7.6% from 3.4% a year ago, supported by a 46% growth in external business and material cost efficiencies. In the pharmacy segment, the company strategically exited loss-making wholesale segments, allowing the business to achieve EBITDA break-even this quarter.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls